Media Contact Information:

Katie Engleman
Pure Communications, Inc.
Katie@purecommunicationsinc.com

<< Back to Articles

Igenica to Present New Data at the World ADC Summit

BURLINGAME, Calif. – February 13, 2014 – Igenica, Inc., a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it will present insights into its proteomic target discovery platform and ADC technology during a plenary session of the World ADC meeting, being held February 17-20 in Frankfurt, Germany.

The schedule for the presentation is as follows:

Date & Time: Tuesday, February 18, 2014, 4:30 p.m. CET

Session: Approaches for Maximizing Therapeutic Index

Title: Disease Relevant Targets for the Development of Next Generation ADCs

Presenter: Thi-Sau Migone, Ph.D., Chief Scientific Officer of Igenica

For more information about the conference, see the full program here.

About Igenica, Inc.

Igenica, Inc. is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Igenica is the only biotherapeutic company that fully powers the ADC development spectrum from a patient-based approach to target and functional antibody discovery to the generation and manufacturing of homogeneous ADCs. Igenica’s integrated discovery engine has generated a robust pipeline of site-specific ADC candidates and functional antibodies to address critical needs of cancer patients. Led by a proven team of leaders with expertise in the development of therapeutic antibodies and ADCs, Igenica is funded by a premier group of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. For more information, please visit www.igenica.com.

Contact

Katie Wilson
Pure Communications Inc.
910-509-3977
katie@purecommunicationsinc.com